NEW PROTOCOL FOR IAD TREATMENT IN PEDIATRIC PATIENTS: STABLE OZONIDES

NEW PROTOCOL FOR IAD TREATMENT IN PEDIATRIC PATIENTS: STABLE OZONIDES Serena Crucianelli1 , Guido Ciprandi2 , Mauro Pace3 , Valentina Vanzi4 , Monica Rossi5 , Giancarlo Antonielli6 1 Sapienza University of Rome, Internal Medicine and Medical Specialties, Roma, Italy 2 Bambino Gesù Children Hospital, Plastic and Maxillofacial surgery, Rome 3 Bambino Gesù Children Hospital, Intensive Care Unit, Rome 4 Bambino Gesù Children Hospital, Department of Pediatric Science , Rome 5 Bambino Gesù Children Hospital, Rome 6 Bambino Gesù Children Hospital, Odontostomatology, Rome Introduction: Incontinence associated dermatitis (IAD) in pediatric population is often a neglected or misdiagnosed issue frequently confused with diaper dermatitis and its treatment is still limited to strong cleansing and hygienic practices followed by thick creams applications. The traditional approach is not respectful of pain caused by thick cream removal at each change. We present results obtained on a consecutive series of children presenting with different grade of IAD treated with a protocol consisting in the application of new stable Ozonides-based products. Methods: Since March 2022 Children aged 0 to 18, presenting with any GLOBIAD stage of IAD, were enrolled in the study. The sample followed a specific protocol at changes based on stable ozonides products (spray and barrier cream application) (Table 1). Pain at changes and healing progression were monitored respectively at each diaper change and daily. Care givers were asked to compile an audit on “feasibility of ozonides protocol application” eventually comparing it to the traditional approach when previously experimented. Results: From March 2022 to April 2024, 35 consecutive children, average 2.2 +/- 1.6 years were included in the study. GLOBIAD staging was: 11.4% 1A; 5.71% 1B; 45.71% 2A; 37.14% 2B. A dramatical decrease was observed after 24hours since first application. No superinfections nor adverse events or allergies occurred during treatment. Re-epithelization occurred after a mean of 7.3 days (Fig. 1A;B;C); no scarring sequelae, neither pigmentation alterations occurred. No relapses occurred when barrier cream was used as maintenance treatment. Conclusions: Stable ozonides products are a valid, practical, and safe option for IAD treatment in pediatric population, regardless of its stage and causing pathology. References: 1. Marinova, P. (2023). THE EFFECT OF TOPICAL APPLICATION WITH OZOILE® AS A NOVEL METHOD IN THE COMPLEX TREATMENT OF SOFT TISSUE INFECTIONS AND CHRONIC WOUNDS. Trakia Journal of Sciences, 21(3).